NDA 20-262/S-036

Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492

Attention: Susan H. Behling
Director, Oncology Global Strategic Unit, Regulatory Science

Dear Ms. Behling:

Please refer to your supplemental new drug application dated December 21, 1999, received December 21, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Taxol (paclitaxel) Injection.

We acknowledge receipt of your submissions dated February 22 and 29, April 17, May 22, and June 5, 2000.

This supplemental new drug application provides for a 3-hour infusion of Taxol (paclitaxel) Injection given every 3 weeks at a dose of 175 mg/m^2 followed by cisplatin at a dose of 75 mg/m^2 for the first-line treatment of advanced ovarian cancer.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-262/S-036." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitment specified in your submission dated June 20, 2000. This commitment is listed below.

> Bristol-Myers Squibb will agree to a Phase IV commitment to provide results of an evaluation of the duration of neurotoxicity when Taxol is given as a 3 hour infusion in combination with a platinum. These analyses will be conducted initially with data from completed or nearly completed trials. If the Agency determines that the duration of toxicity cannot be adequately characterized from these data, Bristol-Myers Squibb will perform a Phase IV study to evaluate duration of

toxicity with this drug combination.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.81(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Christy Wilson, Consumer Safety Technician, at (301) 594-5761.

Sincerely,

Robert Justice, M.D.
Deputy Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research